Veracyte (VCYT) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.51
- Estimate
- $0.41
- Surprise
- +24.5%
- Score today
- 6.3/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Veracyte (VCYT) beat the $0.41 estimate with adjusted EPS of $0.51 — a large 24.5% upside surprise.
Coverage in the report window
- Needham Maintains Buy on Veracyte, Lowers Price Target to $46 — benzinga, 2026-11-05
Where TrendMatrix's rating stands now
TrendMatrix currently rates VCYT Hold at 6.3/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +24.5% surprise compares with a +33.8% four-quarter average.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (4/4)
What argues against it
- Concentration risk — Product: Decipher Prostate and Afirma tests
- Concentration risk — Supplier: sole suppliers for reagents and equipment
- Analyst target reached - limited upside remaining
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $52.52
- Stop
- $48.84
The stock trades at 37.5× trailing but 27.0× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: RSI 73 — a level conventionally read as overbought; gains at these levels often lean on momentum; trading volume is running 1.6× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-11-05 — shown for context, not personalized investment advice.
VCYT at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Diagnostics & Research
- Market cap
- $4.22B
- P/E (fwd)
- 27.0
- P/E (ttm)
- 37.5
- 52-week range
- $29.45–$60.91
- Off 52-week high
- 13.8%
- RSI (14)
- 73
- Volume vs avg
- 1.63×
- Score today
- 6.3/10